A Phase 2 interventional study of Ibrutinib and Lenalidomide in Lymphoma, Mantle-Cell, sponsored by Janssen Research & Development, LLC. Completed at 66 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-07.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 45 studies testing ibrutinib in Lymphoma, Mantle-Cell — 2 open to participants now, 16 under way, 2 of them phase 3. ibrutinib · Lymphoma, Mantle-Cell.
Among the 45 studies testing ibrutinib in Lymphoma, Mantle-Cell, this one is the 25th largest by enrollment, is one of 2 that started in 2022, is one of 21 in phase 2, and was the 43rd registered.
1,221 studies on the registry are indexed under Lymphoma, Mantle-Cell; 154 are open to participants now.
Browse Lymphoma, Mantle-Cell studies →2 of the 45 studies testing ibrutinib in Lymphoma, Mantle-Cell are open now, in 6 countries. Recruiting first, the newest first:
OHSU Knight Cancer Institute · Sites in United States
Ages 18+
Prof. Dr. M. Dreyling (co-chairman) · Sites in Denmark, Germany, Italy and 2 more countries
Ages 18–65
By country, each count listing its studies:
ibrutinib: first FDA approval 2013 (IMBRUVICA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 124 Lymphoma, Mantle-Cell studies recruiting now, 92 (74%) set no upper age limit and 12 (10%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
45 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 26 · Phase 3 6 · Phase 4 1
First in 2009; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 36 is close to the median of 37 across 1,001 interventional studies indexed under Lymphoma, Mantle-Cell.
Median enrollment 39 across the 45 interventional studies. Of the 24 that completed or were terminated, 12 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 45 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 933 studies on the registry; 77 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
16 studies in Lymphoma, Mantle-Cell by Johnson & Johnson: none open now, 1 under way, 1 of them phase 3. Of 13 finished, 5 (38%) have results posted.
Among the 16 studies in Lymphoma, Mantle-Cell by Johnson & Johnson, this one is the 7th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2022, is one of 4 in phase 2, and was the 16th registered.
Johnson & Johnson’s Lymphoma, Mantle-Cell studies by the year they started, since 2012.
6 of the studies testing ibrutinib in Lymphoma, Mantle-Cell that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01804686Phase 3Janssen Research & Development, LLCA Long-term Extension Study of PCI-32765 (Ibrutinib) | 2026-12-31 |
| NCT01479842Kami Maddocks, MDRituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma | 2026-12-01 |
| NCT03710772M.D. Anderson Cancer CenterIbrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma | 2027-03-22 |
| NCT03153202Joshua BrodyStudy to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL) | 2027-04 |
| NCT02427620M.D. Anderson Cancer CenterIbrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma | 2027-06-30 |
Add all 6 to your calendar (.ics) → With an account.
Among the 45 studies testing ibrutinib in Lymphoma, Mantle-Cell, from their registry updates:
Among Johnson & Johnson’s 16 in Lymphoma, Mantle-Cell:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to provide continued access to treatment for participants who continue to benefit from treatment.
Mantle cell lymphoma (MCL) is an uncommon and incurable clinicopathologic subtype of B-cell non-Hodgkin Lymphoma (NHL). Ibrutinib is a first-in-class potent, orally administered, covalently-binding small molecule inhibitor of Bruton's tyrosine kinase (BTKi) for the treatment of B-cell malignancies and chronic graft-versus-host disease. The primary hypothesis of the study is to provide continued access to treatment for participants who continue to benefit from treatment. The study will include a screening phase (up to 30 days prior to randomization), a treatment phase (from randomization until study treatment discontinuation). safety assessments include adverse events (AEs), serious adverse events (SAEs), clinical laboratory tests, vital signs, electrocardiogram (ECG), physical examination. The Phase 2 exploratory objectives and endpoints of characterization of pharmacokinetic and pharmacodynamic of ibrutinib may continue to be evaluated using blood samples already collected. The total duration of the study will be up to 2 years 1 month.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive rituximab 375 milligrams per meter square (mg/m\^2) intravenously (IV) on Day 1 of Cycles 1 to 6 with ibrutinib 560 milligrams (mg) orally, once daily starting on Day 1 of Cycle 1 until disease progression or unacceptable toxicity (each cycle length is 28 days).
Drug: Ibrutinib · Drug: Rituximab
Participants will receive rituximab 375 mg/m\^2 IV on Day 1 of Cycles 1 to 6 with ibrutinib 420 mg orally, once daily starting on Day 1 of Cycle 1 until disease progression or unacceptable toxicity (each cycle length is 28 days).
Drug: Ibrutinib · Drug: Rituximab
Participants will receive rituximab 375 mg/m\^2 IV on Day 1 of Cycles 1 to 6 with ibrutinib 140 mg orally, twice daily starting on Day 1 of Cycle 1 until disease progression or unacceptable toxicity (each cycle length is 28 days).
Drug: Ibrutinib · Drug: Rituximab
Participants will receive rituximab 375 mg/m\^2 IV on Day 1 of Cycles 1 to 6 (each cycle length is 21 or 28 days) with physician's choice of either lenalidomide 20 mg orally, once daily from Day 1 through Day 21 of 28-day cycle or bortezomib 1.3 mg/m\^2 IV or subcutaneously (SC) on Days 1, 4, 8 and 11 of a 21-day cycle until disease progression or unacceptable toxicity.
Drug: Lenalidomide · Drug: Rituximab · Drug: Bortezomib
Ibrutinib capsules will be administered orally.
Also known as: JNJ-54179060, IMBRUVICA, PCI-32765
Lenalidomide capsules will be administered orally.
Rituximab will be administered IV.
Bortezomib will be administered either intravenously or subcutaneously.
Number of Participants With Treatment Emergent Adverse Events (TEAEs) Leading to Discontinuation of Treatment: Arms A1, A2, A3 and B
An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. TEAEs was defined as any new or worsening AE occurring at or after first dose of study treatment up to 30 days after last dose or prior to start of subsequent anticancer therapy, whichever occurred first. All TEAEs including serious and non-serious events were reported in this outcome measure.
Time frame: From start of treatment (Day 1) up to 30 days after last dose of study drug or start of subsequent anticancer therapy, whichever occurred first (up to 12 months)
Number of Participants With Treatment Emergent Adverse Events (TEAEs) Leading to Discontinuation of Treatment: Monotherapy Arm
An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. TEAEs was defined as any new or worsening AE occurring at or after first dose of study treatment up to 30 days after last dose or prior to start of subsequent anticancer therapy, whichever occurred first. All TEAEs included serious and non-serious events were reported in this outcome measure.
Time frame: From start of monotherapy (post protocol amendment 1, dated 08 June 2023) up to 30 days after last dose of study drug or start of subsequent anticancer therapy, whichever occurred first (up to 6 months)
Number of Participants With Grade 3 or Higher TEAEs Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version (v) 5.0: Arms A1, A2, A3 and B
An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. TEAEs was defined as any new or worsening AE occurring at or after first dose of study treatment up to 30 days after last dose or prior to start of subsequent anticancer therapy, whichever occurred first. TEAEs were graded according to NCI-CTCAE v5.0 as Grade 1- Mild; Grade 2- Moderate; Grade 3- Severe or medically significant but not immediately life-threatening; Grade 4- Life-threatening consequences and Grade 5- Death related to AE. Number of participants with grade 3 or higher TEAEs (including serious and non-serious events) were reported in this outcome measure.
Time frame: From start of treatment (Day 1) up to 30 days after last dose of study drug or start of subsequent anticancer therapy, whichever occurred first (up to 12 months)
Number of Participants With Grade 3 or Higher TEAEs Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version (v) 5.0: Monotherapy Arm
An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. TEAEs was defined as any new or worsening AE occurring at or after first dose of study treatment up to 30 days after last dose or prior to start of subsequent anticancer therapy, whichever occurred first. TEAEs were graded according to NCI-CTCAE v5.0 as Grade 1- Mild; Grade 2- Moderate; Grade 3- Severe or medically significant but not immediately life-threatening; Grade 4- Life-threatening consequences and Grade 5- Death related to AE. Number of participants with grade 3 or higher TEAEs (including serious and non-serious events) were reported in this outcome measure.
Time frame: From start of monotherapy (post protocol amendment 1, dated 08 June 2023) up to 30 days after last dose of study drug or start of subsequent anticancer therapy, whichever occurred first (up to 6 months)
Number of Participants With Treatment Emergent Serious Adverse Events (TESAEs): Arms A1, A2, A3 and B
An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. A serious AE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a suspected transmission of any infectious agent via a medicinal product, or was medically important. TESAEs was defined as SAEs occurring at or after first dose of study treatment up to 30 days after last dose or prior to start of subsequent anticancer therapy, whichever occurred first.
Time frame: From start of treatment (Day 1) up to 30 days after last dose of study drug or start of subsequent anticancer therapy, whichever occurred first (up to 12 months)
Number of Participants With Treatment Emergent Serious Adverse Events (TESAEs): Monotherapy Arm
An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. A serious AE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a suspected transmission of any infectious agent via a medicinal product, or was medically important. TESAEs was defined as SAEs occurring at or after first dose of study treatment up to 30 days after last dose or prior to start of subsequent anticancer therapy, whichever occurred first.
Time frame: From start of monotherapy (post protocol amendment 1, dated 08 June 2023) up to 30 days after last dose of study drug or start of subsequent anticancer therapy, whichever occurred first (up to 6 months)
Number of Participants With Clinical Laboratory Abnormalities: Hematology Parameters: Arms A1, A2, A3 and B
Number of participants with clinical abnormalities in hematology laboratory parameters were reported. Hematology parameters included: Activated partial thromboplastin time (aPTT), hemoglobin, neutrophil count, white blood cell (WBC) count, lymphocyte count, platelet count and prothrombin international normalized ratio (INR). Abnormality criteria was assessed as per NCI CTCAE v5.0 grading, where Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening. Grade 0 was assigned when the laboratory value was not assigned a Grade 1 or higher. Only those categories in which at least 1 participant had data were reported.
Time frame: From start of treatment (Day 1) up to 30 days after last dose of study drug (up to 12 months)
Number of Participants With Clinical Laboratory Abnormalities: Hematology Parameters: Monotherapy Arm
Number of participants with clinical abnormalities in hematology laboratory parameters were reported. Hematology parameters included: Activated partial thromboplastin time (aPTT), hemoglobin, neutrophil count, white blood cell (WBC) count, lymphocyte count, platelet count and prothrombin international normalized ratio (INR). Abnormality criteria was assessed as per NCI CTCAE v5.0 grading, where Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening. Grade 0 was assigned when the laboratory value was not assigned a Grade 1 or higher. Only those categories in which at least 1 participant had data were reported.
Time frame: From start of monotherapy (post protocol amendment 1, dated 08 June 2023) up to 30 days after last dose of study drug (up to 6 months)
Number of Participants With Clinical Laboratory Abnormalities: Chemistry Parameters: Arms A1, A2, A3 and B
Number of participants with clinical abnormalities in chemistry laboratory parameters were reported. Chemistry parameters included: sodium, aspartate aminotransferase (AST), potassium, alanine aminotransferase (ALT), creatinine, total bilirubin (BL), alkaline phosphatase, albumin, and calcium. Abnormality criteria was assessed as per NCI CTCAE v5.0 grading, where Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening. Grade 0 was assigned when the laboratory value was not assigned a Grade 1 or higher. Only those categories in which at least 1 participant had data were reported.
Time frame: From start of treatment (Day 1) up to 30 days after last dose of study drug (up to 12 months)
Number of Participants With Clinical Laboratory Abnormalities: Chemistry Parameters: Monotherapy Arm
Number of participants with clinical abnormalities in chemistry laboratory parameters were reported. Chemistry parameters included: sodium, aspartate aminotransferase (AST), potassium, alanine aminotransferase (ALT), creatinine, total bilirubin, alkaline phosphatase, albumin, and calcium. Abnormality criteria was assessed as per NCI CTCAE v5.0 grading, where Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening. Grade 0 was assigned when the laboratory value was not assigned a Grade 1 or higher. Only those categories in which at least 1 participant had data were reported.
Time frame: From start of monotherapy (post protocol amendment 1, dated 08 June 2023) up to 30 days after last dose of study drug (up to 6 months)
| Milestone | Arm A1: Ibrutinib 560 mg + Rituximab 375 mg/m^2 | Arm A2: Ibrutinib 420 mg + Rituximab 375 mg/m^2 | Arm A3: Ibrutinib 140 mg + Rituximab 375 mg/m^2 | Arm B: Lenalidomide 20 mg (or 10 mg if CrCl Was 30 to <60 mL/Min) + Rituximab 375 mg/m^2 |
|---|---|---|---|---|
| Started | 10 | 9 | 8 | 9 |
| Participants who switched to ibrutinib monotherapy | 0 | 4 | 3 | 2 |
| Completed | 10 | 9 | 8 | 8 |
| Not completed | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 |
An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. TEAEs was defined as any new or worsening AE occurring at or after first dose of study treatment up to 30 days after last dose or prior to start of subsequent anticancer therapy, whichever occurred first. All TEAEs including serious and non-serious events were reported in this outcome measure.
| Participants | Arm A1: Ibrutinib 560 mg + Rituximab 375 mg/m^2 | Arm A2: Ibrutinib 420 mg + Rituximab 375 mg/m^2 | Arm A3: Ibrutinib 140 mg + Rituximab 375 mg/m^2 | Arm B: Lenalidomide 20 mg (or 10 mg if CrCl Was 30 to <60 mL/Min) + Rituximab 375 mg/m^2 |
|---|---|---|---|---|
| Discontinuation of Treatment Ibrutinib/Lenalidomide | 1 | 0 | 0 | 2 |
| Discontinuation of Treatment Rituximab | 0 | 1 | 0 | 1 |
An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. TEAEs was defined as any new or worsening AE occurring at or after first dose of study treatment up to 30 days after last dose or prior to start of subsequent anticancer therapy, whichever occurred first. All TEAEs included serious and non-serious events were reported in this outcome measure.
| Participants | Monotherapy Arm: Ibrutinib 560 mg |
|---|---|
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) Leading to Discontinuation of Treatment: Monotherapy Arm | 1 |
An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. TEAEs was defined as any new or worsening AE occurring at or after first dose of study treatment up to 30 days after last dose or prior to start of subsequent anticancer therapy, whichever occurred first. TEAEs were graded according to NCI-CTCAE v5.0 as Grade 1- Mild; Grade 2- Moderate; Grade 3- Severe or medically significant but not immediately life-threatening; Grade 4- Life-threatening consequences and Grade 5- Death related to AE. Number of participants with grade 3 or higher TEAEs (including serious and non-serious events) were reported in this outcome measure.
| Participants | Arm A1: Ibrutinib 560 mg + Rituximab 375 mg/m^2 | Arm A2: Ibrutinib 420 mg + Rituximab 375 mg/m^2 | Arm A3: Ibrutinib 140 mg + Rituximab 375 mg/m^2 | Arm B: Lenalidomide 20 mg (or 10 mg if CrCl Was 30 to <60 mL/Min) + Rituximab 375 mg/m^2 |
|---|---|---|---|---|
| Number of Participants With Grade 3 or Higher TEAEs Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version (v) 5.0: Arms A1, A2, A3 and B | 7 | 3 | 5 | 8 |
An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. TEAEs was defined as any new or worsening AE occurring at or after first dose of study treatment up to 30 days after last dose or prior to start of subsequent anticancer therapy, whichever occurred first. TEAEs were graded according to NCI-CTCAE v5.0 as Grade 1- Mild; Grade 2- Moderate; Grade 3- Severe or medically significant but not immediately life-threatening; Grade 4- Life-threatening consequences and Grade 5- Death related to AE. Number of participants with grade 3 or higher TEAEs (including serious and non-serious events) were reported in this outcome measure.
| Participants | Monotherapy Arm: Ibrutinib 560 mg |
|---|---|
| Number of Participants With Grade 3 or Higher TEAEs Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version (v) 5.0: Monotherapy Arm | 1 |
An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. A serious AE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a suspected transmission of any infectious agent via a medicinal product, or was medically important. TESAEs was defined as SAEs occurring at or after first dose of study treatment up to 30 days after last dose or prior to start of subsequent anticancer therapy, whichever occurred first.
| Participants | Arm A1: Ibrutinib 560 mg + Rituximab 375 mg/m^2 | Arm A2: Ibrutinib 420 mg + Rituximab 375 mg/m^2 | Arm A3: Ibrutinib 140 mg + Rituximab 375 mg/m^2 | Arm B: Lenalidomide 20 mg (or 10 mg if CrCl Was 30 to <60 mL/Min) + Rituximab 375 mg/m^2 |
|---|---|---|---|---|
| Number of Participants With Treatment Emergent Serious Adverse Events (TESAEs): Arms A1, A2, A3 and B | 4 | 3 | 2 | 5 |
An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. A serious AE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a suspected transmission of any infectious agent via a medicinal product, or was medically important. TESAEs was defined as SAEs occurring at or after first dose of study treatment up to 30 days after last dose or prior to start of subsequent anticancer therapy, whichever occurred first.
| Participants | Monotherapy Arm: Ibrutinib 560 mg |
|---|---|
| Number of Participants With Treatment Emergent Serious Adverse Events (TESAEs): Monotherapy Arm | 1 |
Number of participants with clinical abnormalities in hematology laboratory parameters were reported. Hematology parameters included: Activated partial thromboplastin time (aPTT), hemoglobin, neutrophil count, white blood cell (WBC) count, lymphocyte count, platelet count and prothrombin international normalized ratio (INR). Abnormality criteria was assessed as per NCI CTCAE v5.0 grading, where Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening. Grade 0 was assigned when the laboratory value was not assigned a Grade 1 or higher. Only those categories in which at least 1 participant had data were reported.
| Participants | Arm A1: Ibrutinib 560 mg + Rituximab 375 mg/m^2 | Arm A2: Ibrutinib 420 mg + Rituximab 375 mg/m^2 | Arm A3: Ibrutinib 140 mg + Rituximab 375 mg/m^2 | Arm B: Lenalidomide 20 mg (or 10 mg if CrCl Was 30 to <60 mL/Min) + Rituximab 375 mg/m^2 |
|---|---|---|---|---|
| aPTT Prolonged Grade 1 | 1 | — | — | — |
| Hemoglobin Decreased Grade 0 | 3 | 2 | 2 | 0 |
| Hemoglobin Decreased Grade 1 | 3 | 6 | 4 | 5 |
| Hemoglobin Decreased Grade 2 | 3 | 1 | 1 | 1 |
| Hemoglobin Decreased Grade 3 | 1 | 0 | 1 | 3 |
| Hemoglobin Increased Grade 0 | 10 | 9 | 8 | 9 |
| Lymphocyte Count Decreased Grade 0 | 4 | 5 | 7 | 3 |
| Lymphocyte Count Decreased Grade 1 | 3 | 0 | 1 | 2 |
| Lymphocyte Count Decreased Grade 2 | 2 | 4 | 0 | 2 |
| Lymphocyte Count Decreased Grade 3 | 1 | 0 | 0 | 1 |
| Lymphocyte Count Decreased Grade 4 | 0 | 0 | 0 | 1 |
| Lymphocyte Count Increased Grade 0 | 8 | 8 | 7 | 6 |
| Lymphocyte Count Increased Grade 2 | 2 | 1 | 1 | 2 |
| Lymphocyte Count Increased Grade 3 | 0 | 0 | 0 | 1 |
| Neutrophil Count Decreased Grade 0 | 4 | 7 | 4 | 1 |
| Neutrophil Count Decreased Grade 1 | 1 | 1 | 0 | 1 |
| Neutrophil Count Decreased Grade 2 | 1 | 0 | 0 | 1 |
| Neutrophil Count Decreased Grade 3 | 2 | 1 | 4 | 2 |
| Neutrophil Count Decreased Grade 4 | 2 | 0 | 0 | 4 |
| Platelet Count Decreased Grade 0 | 2 | 2 | 5 | 1 |
| Platelet Count Decreased Grade 1 | 4 | 5 | 2 | 3 |
| Platelet Count Decreased Grade 2 | 2 | 1 | 0 | 3 |
| Platelet Count Decreased Grade 3 | 2 | 0 | 0 | 0 |
| Platelet Count Decreased Grade 4 | 0 | 1 | 1 | 2 |
| Prothrombin INR Increased Grade 0 | 1 | — | — | — |
| WBC Decreased Grade 0 | 3 | 4 | 5 | 3 |
| WBC Decreased Grade 1 | 5 | 5 | 3 | 2 |
| WBC Decreased Grade 2 | 1 | 0 | 0 | 3 |
| WBC Decreased Grade 3 | 1 | 0 | 0 | 0 |
| WBC Decreased Grade 4 | 0 | 0 | 0 | 1 |
| WBC Increased Grade 0 | 10 | 9 | 8 | 8 |
| WBC Increased Grade 3 | 0 | 0 | 0 | 1 |
Number of participants with clinical abnormalities in hematology laboratory parameters were reported. Hematology parameters included: Activated partial thromboplastin time (aPTT), hemoglobin, neutrophil count, white blood cell (WBC) count, lymphocyte count, platelet count and prothrombin international normalized ratio (INR). Abnormality criteria was assessed as per NCI CTCAE v5.0 grading, where Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening. Grade 0 was assigned when the laboratory value was not assigned a Grade 1 or higher. Only those categories in which at least 1 participant had data were reported.
| Participants | Monotherapy Arm: Ibrutinib 560 mg |
|---|---|
| aPTT Prolonged Grade 0 | 1 |
| Hemoglobin Increased Grade 0 | 8 |
| Hemoglobin Decreased Grade 0 | 2 |
| Hemoglobin Decreased Grade 1 | 5 |
| Hemoglobin Decreased Grade 2 | 1 |
| Lymphocyte Count Decreased Grade 0 | 5 |
| Lymphocyte Count Decreased Grade 1 | 1 |
| Lymphocyte Count Decreased Grade 2 | 1 |
| Lymphocyte Count Decreased Grade 4 | 1 |
| Lymphocyte Count Increased Grade 0 | 8 |
| Neutrophil Count Decreased Grade 0 | 6 |
| Neutrophil Count Decreased Grade 1 | 1 |
| Neutrophil Count Decreased Grade 2 | 1 |
| Platelet Count Decreased Grade 0 | 2 |
| Platelet Count Decreased Grade 1 | 6 |
| Prothrombin INR Increased Grade 0 | 1 |
| WBC Decreased Grade 0 | 5 |
| WBC Decreased Grade 1 | 3 |
| WBC Increased Grade 0 | 8 |
Number of participants with clinical abnormalities in chemistry laboratory parameters were reported. Chemistry parameters included: sodium, aspartate aminotransferase (AST), potassium, alanine aminotransferase (ALT), creatinine, total bilirubin (BL), alkaline phosphatase, albumin, and calcium. Abnormality criteria was assessed as per NCI CTCAE v5.0 grading, where Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening. Grade 0 was assigned when the laboratory value was not assigned a Grade 1 or higher. Only those categories in which at least 1 participant had data were reported.
| Participants | Arm A1: Ibrutinib 560 mg + Rituximab 375 mg/m^2 | Arm A2: Ibrutinib 420 mg + Rituximab 375 mg/m^2 | Arm A3: Ibrutinib 140 mg + Rituximab 375 mg/m^2 | Arm B: Lenalidomide 20 mg (or 10 mg if CrCl Was 30 to <60 mL/Min) + Rituximab 375 mg/m^2 |
|---|---|---|---|---|
| ALT Increased Grade 0 | 5 | 9 | 8 | 6 |
| ALT Increased Grade 1 | 4 | 0 | 0 | 3 |
| ALT Increased Grade 3 | 1 | 0 | 0 | 0 |
| Albumin Decreased Grade 0 | 6 | 9 | 4 | 7 |
| Albumin Decreased Grade 1 | 2 | 0 | 4 | 1 |
| Albumin Decreased Grade 2 | 2 | 0 | 0 | 1 |
| Alkaline Phosphatase (AP) Increased Grade 0 | 8 | 8 | 5 | 7 |
| AP Increased Grade 1 | 2 | 1 | 3 | 2 |
| AST Increased Grade 0 | 5 | 8 | 8 | 6 |
| AST Increased Grade 1 | 4 | 1 | 0 | 3 |
| AST Increased Grade 3 | 1 | 0 | 0 | 0 |
| Bilirubin (BL) Increased Grade 0 | 7 | 7 | 7 | 8 |
| BL Increased Grade 1 | 2 | 2 | 0 | 1 |
| BL Increased Grade 2 | 0 | 0 | 1 | 0 |
| BL Increased Grade 3 | 1 | 0 | 0 | 0 |
| Calcium Corrected Decreased Grade 0 | 7 | 7 | 6 | 6 |
| Calcium Corrected Decreased Grade 1 | 3 | 2 | 2 | 2 |
| Calcium Corrected Decreased Grade 2 | 0 | 0 | 0 | 1 |
| Calcium Corrected Increased Grade 0 | 10 | 9 | 8 | 8 |
| Calcium Corrected Increased Grade 1 | 0 | 0 | 0 | 1 |
| Creatinine Increased Grade 0 | 9 | 7 | 4 | 6 |
| Creatinine Increased Grade 1 | 1 | 2 | 2 | 3 |
| Creatinine Increased Grade 2 | 0 | 0 | 2 | 0 |
| Potassium Decreased Grade 0 | 7 | 7 | 6 | 9 |
| Potassium Decreased Grade 2 | 2 | 1 | 2 | 0 |
| Potassium Decreased Grade 4 | 1 | 1 | 0 | 0 |
| Potassium Increased Grade 0 | 10 | 8 | 7 | 9 |
| Potassium Increased Grade 2 | 0 | 1 | 1 | 0 |
| Sodium Decreased Grade 0 | 7 | 6 | 5 | 8 |
| Sodium Decreased Grade 1 | 3 | 3 | 3 | 1 |
| Sodium Increased Grade 0 | 8 | 9 | 8 | 8 |
| Sodium Increased Grade 1 | 2 | 0 | 0 | 1 |
Number of participants with clinical abnormalities in chemistry laboratory parameters were reported. Chemistry parameters included: sodium, aspartate aminotransferase (AST), potassium, alanine aminotransferase (ALT), creatinine, total bilirubin, alkaline phosphatase, albumin, and calcium. Abnormality criteria was assessed as per NCI CTCAE v5.0 grading, where Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening. Grade 0 was assigned when the laboratory value was not assigned a Grade 1 or higher. Only those categories in which at least 1 participant had data were reported.
| Participants | Monotherapy Arm: Ibrutinib 560 mg |
|---|---|
| ALT Increased Grade 0 | 8 |
| Albumin Decreased Grade 0 | 6 |
| Albumin Decreased Grade 1 | 2 |
| Alkaline Phosphatase Increased Grade 0 | 8 |
| AST Increased Grade 0 | 8 |
| Bilirubin Increased Grade 0 | 8 |
| Calcium Corrected Decreased Grade 0 | 7 |
| Calcium Corrected Decreased Grade 1 | 1 |
| Calcium Corrected Increased Grade 0 | 8 |
| Creatinine Increased Grade 0 | 7 |
| Creatinine Increased Grade 1 | 1 |
| Potassium Decreased Grade 0 | 7 |
| Potassium Decreased Grade 2 | 1 |
| Potassium Increased Grade 0 | 8 |
| Sodium Decreased Grade 0 | 5 |
| Sodium Decreased Grade 1 | 3 |
| Sodium Increased Grade 0 | 8 |
Collected over Arm A1, A2, A3 and B: From start of treatment (Day 1) up to 30 days after last dose of study drug or start of subsequent anticancer therapy, whichever occurred first (up to 12 months); Monotherapy arm: From start of monotherapy (post protocol amendment 1, dated 08 June 2023) up to 30 days after last dose of study drug or start of subsequent anticancer therapy, whichever occurred first (up to 6 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A1: Ibrutinib 560 mg + Rituximab 375 mg/m^2 | 1/10 (10%) | 4/10 (40%) | 10/10 (100%) |
| Arm A2: Ibrutinib 420 mg + Rituximab 375 mg/m^2 | 0/9 (0%) | 3/9 (33.3%) | 7/9 (77.8%) |
| Arm A3: Ibrutinib 140 mg + Rituximab 375 mg/m^2 | 1/8 (12.5%) | 2/8 (25%) | 8/8 (100%) |
| Arm B: Lenalidomide 20 mg (or 10 mg if CrCl Was 30 to <60 mL/Min) + Rituximab 375 mg/m^2 | 2/9 (22.2%) | 5/9 (55.6%) | 8/9 (88.9%) |
| Monotherapy Arm: Ibrutinib 560 mg | 0/9 (0%) | 1/9 (11.1%) | 4/9 (44.4%) |
| Event | Arm A1: Ibrutinib 560 mg + Rituximab 375 mg/m^2 | Arm A2: Ibrutinib 420 mg + Rituximab 375 mg/m^2 | Arm A3: Ibrutinib 140 mg + Rituximab 375 mg/m^2 | Arm B: Lenalidomide 20 mg (or 10 mg if CrCl Was 30 to <60 mL/Min) + Rituximab 375 mg/m^2 | Monotherapy Arm: Ibrutinib 560 mg |
|---|---|---|---|---|---|
| Febrile NeutropeniaBlood and lymphatic system disorders | 0/10 | 0/9 | 0/8 | 2/9 | 0/9 |
| PneumoniaInfections and infestations | 0/10 | 1/9 | 1/8 | 0/9 | 1/9 |
| Papillary Thyroid CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/10 | 0/9 | 1/8 | 0/9 | 0/9 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/10 | 1/9 | 0/8 | 1/9 | 0/9 |
| Supraventricular TachycardiaCardiac disorders | 0/10 | 1/9 | 0/8 | 0/9 | 0/9 |
| SepsisInfections and infestations | 0/10 | 0/9 | 0/8 | 1/9 | 0/9 |
| Septic ShockInfections and infestations | 0/10 | 0/9 | 0/8 | 1/9 | 0/9 |
| Skin InfectionInfections and infestations | 0/10 | 0/9 | 0/8 | 1/9 | 0/9 |
| Adenocarcinoma MetastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/10 | 1/9 | 0/8 | 0/9 | 0/9 |
| NeutropeniaBlood and lymphatic system disorders | 1/10 | 0/9 | 0/8 | 0/9 | 0/9 |
| Event | Arm A1: Ibrutinib 560 mg + Rituximab 375 mg/m^2 | Arm A2: Ibrutinib 420 mg + Rituximab 375 mg/m^2 | Arm A3: Ibrutinib 140 mg + Rituximab 375 mg/m^2 | Arm B: Lenalidomide 20 mg (or 10 mg if CrCl Was 30 to <60 mL/Min) + Rituximab 375 mg/m^2 | Monotherapy Arm: Ibrutinib 560 mg |
|---|---|---|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 4/10 | 1/9 | 4/8 | 4/9 | 0/9 |
| HypertensionVascular disorders | 5/10 | 1/9 | 0/8 | 0/9 | 0/9 |
| DiarrhoeaGastrointestinal disorders | 1/10 | 0/9 | 3/8 | 0/9 | 0/9 |
| AnaemiaBlood and lymphatic system disorders | 1/10 | 0/9 | 1/8 | 3/9 | 0/9 |
| ThrombocytopeniaBlood and lymphatic system disorders | 1/10 | 0/9 | 0/8 | 3/9 | 0/9 |
| Periorbital OedemaEye disorders | 0/10 | 0/9 | 2/8 | 0/9 | 0/9 |
| Blood Creatinine IncreasedInvestigations | 0/10 | 0/9 | 2/8 | 0/9 | 0/9 |
| Platelet Count DecreasedInvestigations | 0/10 | 0/9 | 2/8 | 2/9 | 0/9 |
| PneumoniaInfections and infestations | 0/10 | 2/9 | 1/8 | 0/9 | 0/9 |
| Upper Respiratory Tract InfectionInfections and infestations | 2/10 | 1/9 | 0/8 | 1/9 | 1/9 |
| Age, Continuous(Years) | Arm A1: Ibrutinib 560 mg + Rituximab 375 mg/m^2 | Arm A2: Ibrutinib 420 mg + Rituximab 375 mg/m^2 | Arm A3: Ibrutinib 140 mg + Rituximab 375 mg/m^2 | Arm B: Lenalidomide 20 mg (or 10 mg if CrCl Was 30 to <60 mL/Min) + Rituximab 375 mg/m^2 | Total |
|---|---|---|---|---|---|
| Mean | 66.5 ± 7.23 | 68.9 ± 8.08 | 64.6 ± 10.35 | 64.6 ± 7.60 | 66.2 ± 8.13 |
| Sex: Female, Male(Participants) | Arm A1: Ibrutinib 560 mg + Rituximab 375 mg/m^2 | Arm A2: Ibrutinib 420 mg + Rituximab 375 mg/m^2 | Arm A3: Ibrutinib 140 mg + Rituximab 375 mg/m^2 | Arm B: Lenalidomide 20 mg (or 10 mg if CrCl Was 30 to <60 mL/Min) + Rituximab 375 mg/m^2 | Total |
|---|---|---|---|---|---|
| Female | 4 | 3 | 1 | 1 | 9 |
| Male | 6 | 6 | 7 | 8 | 27 |
| Ethnicity (NIH/OMB)(Participants) | Arm A1: Ibrutinib 560 mg + Rituximab 375 mg/m^2 | Arm A2: Ibrutinib 420 mg + Rituximab 375 mg/m^2 | Arm A3: Ibrutinib 140 mg + Rituximab 375 mg/m^2 | Arm B: Lenalidomide 20 mg (or 10 mg if CrCl Was 30 to <60 mL/Min) + Rituximab 375 mg/m^2 | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 3 | 2 | 2 | 3 | 10 |
| Not Hispanic or Latino | 7 | 7 | 6 | 6 | 26 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Arm A1: Ibrutinib 560 mg + Rituximab 375 mg/m^2 | Arm A2: Ibrutinib 420 mg + Rituximab 375 mg/m^2 | Arm A3: Ibrutinib 140 mg + Rituximab 375 mg/m^2 | Arm B: Lenalidomide 20 mg (or 10 mg if CrCl Was 30 to <60 mL/Min) + Rituximab 375 mg/m^2 | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 2 | 2 | 2 | 2 | 8 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 1 | 2 | 4 |
| White | 6 | 7 | 4 | 5 | 22 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 1 | 0 | 2 |
| Region of Enrollment(Participants) | Arm A1: Ibrutinib 560 mg + Rituximab 375 mg/m^2 | Arm A2: Ibrutinib 420 mg + Rituximab 375 mg/m^2 | Arm A3: Ibrutinib 140 mg + Rituximab 375 mg/m^2 | Arm B: Lenalidomide 20 mg (or 10 mg if CrCl Was 30 to <60 mL/Min) + Rituximab 375 mg/m^2 | Total |
|---|---|---|---|---|---|
| BRAZIL | 5 | 2 | 2 | 3 | 12 |
| CZECH REPUBLIC | 0 | 0 | 1 | 0 | 1 |
| GREECE | 0 | 1 | 0 | 0 | 1 |
| MALAYSIA | 2 | 1 | 1 | 0 | 4 |
| POLAND | 1 | 1 | 0 | 2 | 4 |
| SPAIN | 1 | 1 | 1 | 0 | 3 |
| TAIWAN | 0 | 0 | 1 | 0 | 1 |
| THAILAND | 0 | 1 | 0 | 2 | 3 |
| TURKEY | 1 | 2 | 2 | 2 | 7 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Data sharing details ↗ · www.janssen.com
Ran from Dec 2022 to primary completion in Dec 2023, 12 months.
Results were first posted in Jan 2025, 1 year 1 month after primary completion.
Of 30 industry-sponsored phase 2 interventional studies under Lymphoma, Mantle-Cell, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's 12 months is below that.
Counting every sponsor, half of 183 studies reached it within 63 months; a quarter within 38 and three quarters within 106.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ibrutinib · Lenalidomide · Bortezomib
Janssen Research & Development, LLC →